In a Law360 article, health care partner Tom Bulleit (Washington, D.C.), and health care associate Elana Bengualid (New York) examine the current bevy of federal administrative and legislative proposals in the context of existing federal law governing drug prices, with the aim of identifying the future and current effects that such proposals may hold for the drug industry.
The article is the first in a series to examine how the current wave of drug pricing reforms may affect drug companies' business operations and, in particular, their compliance with existing federal price reporting and pricing requirements. The second article will address the implications of state drug pricing initiatives, and the third article will explore enforcement of federal pricing requirements.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.